These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 27565435

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.
    Sanchez L, Nakama T, Nagai H, Matsuoka O, Inoue S, Inoue T, Shrestha A, Pandey A, Chang LJ, De Bruijn I, QHD00010 Study Group.
    Vaccine; 2023 Apr 06; 41(15):2553-2561. PubMed ID: 36906404
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial.
    Robertson CA, Mercer M, Selmani A, Klein NP, Jeanfreau R, Greenberg DP.
    Pediatr Infect Dis J; 2019 Mar 06; 38(3):323-328. PubMed ID: 30395011
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial.
    Sanchez L, Matsuoka O, Inoue S, Inoue T, Meng Y, Nakama T, Kato K, Pandey A, Chang LJ.
    Hum Vaccin Immunother; 2020 Apr 02; 16(4):858-866. PubMed ID: 31634025
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study.
    Hu Y, Chu K, Lavis N, Li X, Liang B, Liu S, Shao M, Shu JD, Tabar C, Samson S.
    Hum Vaccin Immunother; 2019 Apr 02; 15(5):1066-1069. PubMed ID: 30779689
    [Abstract] [Full Text] [Related]

  • 32. Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial.
    Gao Y, Yang X, Li X, Chen H, Li Y, Tan X, Yu D, Feng T, Zhou S, Lei S, Zhao C, Wang J, Guan Q.
    Vaccine; 2024 Aug 30; 42(21):126182. PubMed ID: 39116486
    [Abstract] [Full Text] [Related]

  • 33. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial.
    Pepin S, Nicolas JF, Szymanski H, Leroux-Roels I, Schaum T, Bonten M, Icardi G, Shrestha A, Tabar C, QHD00011 study team.
    Hum Vaccin Immunother; 2021 Dec 02; 17(12):5475-5486. PubMed ID: 34714720
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial.
    Sharma S, Singh VB, Kumar S, Prajapati V, Patel J, Vukkala R, Jangid SK, Sanmukhani J, Gupta G, Patel P, Mittal R, Glueck R.
    Hum Vaccin Immunother; 2018 Jun 03; 14(6):1362-1369. PubMed ID: 29461913
    [Abstract] [Full Text] [Related]

  • 36. Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India.
    Agarkhedkar S, Chhatwal J, Kompithra RZ, Lalwani SK, Narayan A, Muninarayanaswam V, Gogtay N, Dotter K, Gresset-Bourgeois V.
    Hum Vaccin Immunother; 2019 Jun 03; 15(4):973-977. PubMed ID: 30762467
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
    Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD.
    Pediatr Infect Dis J; 2014 Jun 03; 33(6):630-6. PubMed ID: 24445833
    [Abstract] [Full Text] [Related]

  • 39. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
    Song JY, Lee J, Woo HJ, Wie SH, Lee JS, Kim SW, Kim TH, Jung SI, Noh JY, Choi WS, Cheong HJ, Kim WJ.
    Hum Vaccin Immunother; 2019 Jun 03; 15(3):710-716. PubMed ID: 30396317
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.